Safety of micafungin in pediatric clinical trials

Pediatric Infectious Disease Journal

Volumn 30, Issue 6, 2011, Pages

  Arrieta, Antonio C ^a   Maddison, Philip ^b   Groll, Andreas H ^c  

^a CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^b Astellas Pharma Global Development   (Netherlands)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Micafungin; Pediatric; Safety

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMPHOTERICIN B LIPID COMPLEX; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; FLUCONAZOLE; MICAFUNGIN; UREA;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT RESPIRATORY DISTRESS SYNDROME; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ANXIETY; ARTICLE; CYANOSIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FLUSHING; GROUPS BY AGE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATOMEGALY; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; HYPOXIA; INFECTION PREVENTION; INFUSION RELATED REACTION; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LEUKOPENIA; LIVER FUNCTION TEST; MENINGITIS; MUCOSA INFLAMMATION; MYCOSIS; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHLEBITIS; PRIORITY JOURNAL; RIGOR; SIDE EFFECT; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT DURATION; UREA BLOOD LEVEL; VOMITING;

EID: 79958014976     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182127eaf     Document Type: Article

References (18)

1. Blyth CC, Palasanthiran P, O'Brien TA. Antifungal therapy in children with invasive fungal infections: a systematic review. Pediatrics. 2007;119:772-784.
2. Ullmann AJ, Sanz MA, Tramarin A, et al. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis. 2006;43:e29-e38.
3. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004;38:161-189.
4. Eggimann P, Garbino J, Pittet D. Management of Candida species infections in critically ill patients. Lancet Infect Dis. 2003;3:772-785.
5. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003;36:630-637.
6. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007;369:1519-1527.
7. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45:883-893.
8. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39:1407-1416.
9. Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother. 2005;49:3317-3324.
10. Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J. 2006;25:1110-1115.
11. Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect. 2006;53:337-349.
12. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis. 2005;24:654-661.
13. Queiroz-Telles F, Berezin E, Leverger G, et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J. 2008;27:820-826.
14. Benjamin DK Jr, Smith PB, Arrieta A, et al. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther. 2009;87:93-98.
15. Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis. 2008;197:163-171.
16. Astellas Pharma US Inc. Mycamine. Mycamine (micafungin). Prescribing Information. Available at: http://www.mycamine.com/pi.php. Accessed December 2, 2010.
17. Astellas Pharma GmbH. Mycamine: summary of product characteristics. Available at: http://emc.medicines.org.uk/medicine/20997/SPC/Mycamine+50mg+and+100mg+powder+for+solution+for+infusion/. Accessed December 2, 2010.
18. Cornely OA, Maddison P, Ullmann AJ. Pooled analysis of safety for micafungin. Poster presented at: The 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Chicago, IL; 2007. Poster M-1175.